Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-191-9 | CAS number: -
Results for acute oral toxicity were based on a constituent of the target substance. A study similar to OECD401 is performed with CAS 85186-64 -7: LD50> 10000 mg/kg bw. For the substance itself a 14 -day range finder is available which indicates that this substance might be more toxic compared to CAS 85186-64 -7. Overall, the data on acute oral toxicity is inconclusive.
Acute dermal toxicity: A study according to OECD402: LD50 > 2000 mg/kg bw.
For acute oral and inhalation toxicity no substance-specific data are available. Therefore, this information is derived from the consituent with CAS 85186-64 -7. For acute dermal toxicity a study with the test substance itself is available. For the oral route however, the obtained effect level is not in line with the obervations in a 14 -day range finder with the substance itself.
Acute oral toxicity, equivalent to OECD401 (source substance CAS 85186-64 -7)
Gassner rats were exposed by oral gavage to the test substance (5 animals/sex/dose) at dosage levels of 8000 and 10000 mg/kg bw administered as a 30% solution in CMC. Animals were subjected to observations during a period of 7 days in which mortality (observations after 1, 24 and 48 hours and 7 days) and clinical signs were recorded. Necropsy on survivors was performed as well. During the observation period dematiaceous faeces were observed, no further clinical signs or abnormalities on the organs were reported. No mortality occurred. Based on these data, an LD50 of >10000 mg/kg was determined for both males and females (BASF 1972).
14 day dose-range finder with the substance itself
The objective of this dose range finder was to select dose levels for a combined 28-day repeated dose toxicity study with the reproduction/developmental toxicity screening test of in Wistar Han rats by oral gavage. The oral route was selected as it is a possible route of human exposure during manufacture, handling or use of the test item. The substance was administered as a suspension in propylene glycol at dose levels of 1000, 200, 50 and 100 mg/kg bw/day (group 2, 3, 4 and 5) subsequently to 4 males and 4 females. A vehicle control group (group 1 was taken along). Chemical analyses of formulations for Groups 1, 2 and 3 were conducted once during the study to confirm accuracy and homogeneity. No chemical analyses was performed for the last added two Groups 4 and 5. The following parameters and end points were evaluated in this study: clinical signs, bodyweights, food consumption, clinical pathology (haematology, coagulation and clinical chemistry), gross necropsy findings and organ weights. Administration of the substance was not tolerated at dose levels of 100, 200 and 1000 mg/kg bw/day. Within 3 to 5 days (1000 and 200 mg/kg bw/day) and 9 to 11 days (100 mg/kg bw/day) all animals were either found dead or euthanizedin extremis(in the 200 mg/kg bw/day group only). This high toxicity was not expected based on the available data from an acute toxicity study indicating an LD50 > 10000 mg/kg bw/day. General observations prior to their deaths included piloerection (both sexes) and hunched posture (females only), body weight loss and reduced food consumption (absolute and relative to body weight). Severity increased with higher dose, and females seemed to be more sensitive to treatment than males. At necropsy, two females at 1000 mg/kg bw/day had several to many, purple foci on their thymus. In addition, all animals were noted with bluish discoloration of their bodies, including internal tissues/organs, which most likely was related to the black colour of the test item. In these groups, organ weights of liver, kidneys, adrenals and spleen could only be determined for the animals at 200 mg/kg/day that were euthanizedinextremis. Incidental changes included increased weights of liver and kidneys (one male and one female), increased weight of adrenals (one male). No data on clinical laboratory parameters are available from all these animals that died preterm. Only limited toxicity was seen at 50 mg/kg bw/day. In-life findings included piloerection (both sexes) and hunched posture (females only). At end of treatment (Day 15), blood levels of cholesterol were markedly decreased (both sexes). In addition, higher levels of bile acids were recorded in one male and all females. There were no test item-related mortalities, bodyweight and food consumption remained within the normal range, and no clear changes in haematology parameters (incl. clotting) and organ weights were noted. In conclusion, based on the results of this dose range finder, doses of 5, 15 and 50 mg/kg bw/ day were selected for the combined 28-day repeated dose toxicity study with the reproduction/ developmental toxicity screening test (Charles River Laboratories 2018).
Acute inhalation toxicity (source substance CAS 85186-64 -7)
In an inhalation hazard test in rats, 12 male and female rats were exposed to saturated vapour (generated at 200 °C) of the test substance for 8 hours at a mean concentration of 1.58 mg/L. In a one week exposure period, mortality and clinical signs were recorded. Necropsy was scheduled at the end of the exposure period. Observations were performed at 3, 10 and 30 minutes and 1, 3 and 8 hours. Due to a technical problem, which caused all animals to die, the study was discontinued. No conclusion based on this study could be formed. (BASF 1972).
Acute dermal toxicity, OECD 402
In an acute dermal toxicity study (Limit Test according to OECD 402 and GLP), young adult Wistar rats (5 males and 5 females) were dermally exposed to a single dose of 2000 mg/kg bw. The test substance was applied as suspension in corn oil Ph.Eur. The clipped application site (dorsal and dorso-lateral parts of the trunk, comprising at least 10% of the total body surface) was covered by semi-occlusive dressing during the 24-hour exposure period. The animals were observed for 14 days for mortality, clinical sighs and body weight. Gross pathology was performed at the end of the study. During the observation period, no mortality occurred, no signs of systemic toxicity were observed. Local effects were assigned within the first two days after application since due to the black discoloration of the application area, erythema could not be determined from study day 1 until study day 2. The body weights of the male animals and of two female animals increased within the normal range throughout the study period. Two female animals showed a stagnation of body weight during the first week while in another female animal a marginal loss of body weight was noted. Due to the fact that stagnation or marginal loss of body weight is commonly known for females after dermal applications, this stagnation is considered to be unspecific. Based on these data, the LD50 exceeds the limit dose of 2000 mg/kg bw (Bioassay 2016).
Based on the results of the available studies, classification of the substance for acute dermal toxicity is not warranted in accordance with EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation No. (EC) 1272/2008. The data on acute oral toxicity is inconclusive.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again